Related references
Note: Only part of the references are listed.O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
T. Walter et al.
BRITISH JOURNAL OF CANCER (2015)
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka et al.
LANCET ONCOLOGY (2014)
Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms
Anja Maria Schmitt et al.
NEUROENDOCRINOLOGY (2014)
Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
Renata Ferrarotto et al.
RARE TUMORS (2013)
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients
Veronique Quillien et al.
CANCER (2012)
New treatment strategies in advanced neuroendocrine tumours
Thomas Walter et al.
DIGESTIVE AND LIVER DISEASE (2012)
A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine
Cecile Nozieres et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Streptozocin-based chemotherapy is not history in neuroendocrine tumours
Katie Weatherstone et al.
TARGETED ONCOLOGY (2012)
Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours
L. Medley et al.
BRITISH JOURNAL OF CANCER (2011)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
Staffan Welin et al.
CANCER (2011)
Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin
Christoph J. Auernhammer et al.
GUT (2011)
Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors
Thomas Walter et al.
CLINICAL COLORECTAL CANCER (2010)
MGMT-535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy
Jee Hyun Park et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
Lucie Karayan-Tapon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Matthew H. Kulke et al.
PANCREAS (2010)
The Pathologic Classification of Neuroendocrine Tumors A Review of Nomenclature, Grading, and Staging Systems
David S. Klimstra et al.
PANCREAS (2010)
Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas A Single-Center Experience
Philippe A. Cassier et al.
CANCER (2009)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?
T Delaunoit et al.
EUROPEAN JOURNAL OF CANCER (2004)
A phase II trial of gemcitabine for metastatic neuroendocrine tumors
MH Kulke et al.
CANCER (2004)
Share Paper
